Skip to main content
A young girl running forward with her arm outstretched

Seroresponse Data

See subsequent data as to why MenQuadfi and its high rate of seroresponse is a valuable consideration when reviewing your meningococcal vaccine options. Review the full ACIP Schedule.1,2

MenQuadfi elicited an effective seroresponse across all 4 serogroups vs Menveo® and Menactra®1,3*†

MENQUADFI VS MENVEO

Study design: The immunogenicity and safety of MenQuadfi in adolescents 10 through 17 years of age were evaluated in a randomized, head-to-head clinical trial vs Menveo. Analyses included more than 900 participants. Serum was collected at baseline and 30 days post vaccination to measure antibodies with an hSBA.1

Percentage of subjects achieving vaccine seroresponsea at day 30 (primary endpoint)1

Illustration of a bar graph showing MenQuadfi’s effective seroresponse across all 4 serogroups vs Menveo®

MENQUADFI VS MENACTRA

Study design: The immunogenicity and safety of MenQuadfi were evaluated in a randomized, head-to-head clinical trial vs Menactra that included individuals 10 to 55 years of age (N=3344). Analyses were stratified by age, including a subpopulation consisting of nearly 1400 adolescents 10 through 17 years of age. Serum was collected at baseline and 30 days post vaccination to measure antibodies with an hSBA.1,3,4

Seroresponse rates for MenQuadfi were non-inferior to those of Menactra for all serogroups based on the same non-inferiority criteria defined by the MenQuadfi vs Menveo study.1

Percentage of subjects 10-17 years of age achieving vaccine seroresponsea at day 30 (secondary analysis)2

Illustration of a bar graph showing MenQuadfi’s effective seroresponse across all 4 serogroups vs Menactra®
← SEE HOME

  

SEE ACIP SCHEDULE →

Important Safety Information

MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of MenQuadfi.

Some individuals with altered immunocompetence, including some receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and those receiving treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis, including serogroups A, C, W, and Y, even if they develop antibodies following vaccination with MenQuadfi.

Syncope (fainting) may occur in association with administration of injectable vaccines, including MenQuadfi. Procedures should be in place to avoid injury from fainting.

Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons with a history of GBS should take into account the expected benefits and potential risks.

Immunization with MenQuadfi does not substitute for routine tetanus immunization.

Vaccination with MenQuadfi may not protect all vaccine recipients.

The most common adverse reactions following primary vaccination with MenQuadfi in infants 6 weeks through 23 months of age include tenderness, erythema, and swelling at the injection site; irritability, abnormal crying, drowsiness, appetite loss, fever, and vomiting. In individuals 2 years of age and older, the most common adverse reactions include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination. Other adverse reactions may occur.

Please see the full Prescribing Information for MenQuadfi.

Learn more about Sanofi's commitment to fighting counterfeit drugs.

Important Safety Information

ACIP = Advisory Committee on Immunization Practices; CI = confidence interval; hSBA = human serum bactericidal assay; N = number of participants in per-protocol analysis set with valid serology results.
* Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine).
† Menactra (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine).
a Defined as the proportion of participants with an hSBA pre-vaccination titer <1:8 who achieved a post-vaccination titer ≥1:16, or participants with a pre-vaccination titer ≥1:8 who achieved a post-vaccination titer at least 4-fold greater than the pre-vaccination titer.1
b Percent difference: MenQuadfi minus Menveo or Menactra (95% CI).2
c 95% CI of the difference calculated from the Wilson Score method without continuity correction; the overall non-inferiority would be demonstrated if the lower limit of the 2-sided 95% CI is ≥10% for all 4 serogroups.2
d 95% CI of the single proportion calculated from the exact binomial method.1

MenQuadfi is a registered trademark of Sanofi.
Menactra is a registered trademark of Sanofi, its affiliates, and its subsidiaries.
The other brands listed are trademarks owned by or licensed to their respective owners and are not owned by or licensed to Sanofi, its affiliates and/or its subsidiaries.

REFERENCES:
1. MenQuadfi [Prescribing Information]. Sanofi.
2. Collins J; ACIP Meningococcal Vaccines Work Group. National Center for Immunization and Respiratory Diseases. Centers for Disease Control and Prevention. Summary of EtR and proposed recommendations for Pfizer’s MenABCWY vaccine. October 25, 2023. Accessed June 26, 2025. https://stacks.cdc.gov/view/cdc/134696
3. Sanofi. Data on File. July 27, 2020.
4. Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38(33):5194-5201.

MAT-US-2007152-v12.0-11/2025

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContact
© 2025 Sanofi. All rights reserved.